Boston Scientific has received the US Food and Drug Administration (FDA) 510(k) clearance and CE mark approval to market its Advanix biliary plastic stents for the treatment of biliary strictures.
The Advanix biliary stent employs NaviFlex RX delivery system, which offers physicians the flexibility to employ both long-wire and short-wire guidewires during access and stent placement.
The Advanix is designed to accommodate a range of clinical requirements and includes features for improved deliverability in navigating tortuous anatomy.
Boston Scientific Endoscopy Division senior vice president and president Michael Phalen said that the Advanix biliary stent System represents the latest advances in plastic stent design, enabling physicians to more efficiently and effectively treat blockages in the bile duct.
“In addition, it strengthens our stent portfolio and provides another solution for the ERCP suite,” Phalen said.